What Difference Does Patient and Public Involvement Make and What Are Its Pathways to Impact? Qualitative Study of Patients and Researchers from a Cohort of Randomised Clinical Trials.

Autor: Louise Dudley, Carrol Gamble, Jennifer Preston, Deborah Buck, EPIC Patient Advisory Group, Bec Hanley, Paula Williamson, Bridget Young

Publikováno v: PLoS ONE, Vol 10, Iss 6, p e0128817 (2015)

BackgroundPatient and public involvement (PPI) is advocated in clinical trials yet evidence on how to optimise its impact is limited. We explored researchers' and PPI contributors' accounts of the impact of PPI within trials and factors likely to inf

Externí odkaz: https://doaj.org/article/034f40db15ff4944b46db1094c9f134d

Supplemental Table 1 from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Autor: Paresh Vyas, Jamie D. Cavenagh, Michael Dennis, Shamyla Siddique, Richard J. Kelly, Srinivas P. Pillai, Mary Frances McMullin, Keith Wheatley, Louise Dudley, Sandeep Nagra, Manoj Raghavan, Angela Hamblin, Alison Kennedy, Natalia Garcia-Martin, Marlen Metzner, Corran Roberts, Emma Gbandi, Paul Ferguson, Lynn Swun Quek, Aimee E. Houlton, Charles F. Craddock

Table S1. Details for NGS amplicons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2349da5f2731fe9b5293126d52cd1ddb
https://doi.org/10.1158/1078-0432.22468977.v1

Data from Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Autor: Paresh Vyas, Jamie D. Cavenagh, Michael Dennis, Shamyla Siddique, Richard J. Kelly, Srinivas P. Pillai, Mary Frances McMullin, Keith Wheatley, Louise Dudley, Sandeep Nagra, Manoj Raghavan, Angela Hamblin, Alison Kennedy, Natalia Garcia-Martin, Marlen Metzner, Corran Roberts, Emma Gbandi, Paul Ferguson, Lynn Swun Quek, Aimee E. Houlton, Charles F. Craddock

Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0327fb5df6da2c1e7558e937576087
https://doi.org/10.1158/1078-0432.c.6527109

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Autor: Alison Kennedy, Aimee E Houlton, Paul Ferguson, Michael Dennis, Marlen Metzner, Shamyla Siddique, Sandeep Nagra, Keith Wheatley, Natalia Garcia-Martin, Mary Frances McMullin, Lynn Quek, Srinivas Pillai, Jamie Cavenagh, Emma Gbandi, Manoj Raghavan, Richard Kelly, Corran Roberts, Louise Dudley, Angela Hamblin, Paresh Vyas, Charles Craddock

Publikováno v: Craddock, C, Houlton, A E, Quek, L S, Ferguson, P, Gbandi, E, Roberts, C, Metzner, M, Garcia-Martin, N, Kennedy, A, Hamblin, A, Raghavan, M, Nagra, S, Dudley, L, Wheatley, K, McMullin, M, Pillai, S P, kelly, R J, Siddique, S, Dennis, M, Cavenagh, J D & Vyas, P 2017, ' Outcome of azacitidine therapy in acute myeloid leukaemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-17-1423

Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid leukemia (AML), but its rational utilization is compromised by the fact that neither the determinants of clinical response nor its mechanism of action are d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26326dd64b25e6545090d1d151ab6d82
https://doi.org/10.1158/1078-0432.ccr-17-1423

An evidence base to optimise methods for involving patient and public contributors in clinical trials: a mixed-methods study

Autor: Bec Hanley, Louise Dudley, Philip Bell, Jennifer Preston, Heather Goodare, Alison Allam, Paula R Williamson, Alison Walker, Bridget Young, Carrol Gamble, Deborah Buck

Publikováno v: Health Services and Delivery Research
Health Services and Delivery Research, Vol 3, Iss 39 (2015)

BackgroundIn comparison with other study designs, randomised trials are regarded as particularly likely to benefit from patient and public involvement (PPI). Using mixed-methods research we investigated PPI from the perspectives of researchers and PP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::573f946399b038a99963addda37cde07